It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
The role of hepatitis C virus (HCV) coinfection and HCV-RNA in the development of diabetes mellitus (DM) in HIV-positive persons remains unclear.
Methods
Poisson regression was used to compare incidence rates of DM (blood glucose >11.1 mmol/L, HbA1C >6.5% or >48 mmol/mol, starting antidiabetic medicine or physician reported date of DM onset) between current HIV/HCV groups (anti-HCV-negative, spontaneously cleared HCV, chronic untreated HCV, successfully treated HCV, HCV-RNA-positive after HCV treatment).
Results
A total of 16 099 persons were included; at baseline 10 091 (62.7%) were HCV-Ab-negative, 722 (4.5%) were spontaneous clearers, 3614 (22.4%) were chronically infected, 912 (5.7%) had been successfully treated, and 760 (4.7%) were HCV-RNA-positive after treatment. During 136 084 person-years of follow-up (PYFU; median [interquartile range], 6.9 [3.6–13.2]), 1108 (6.9%) developed DM (crude incidence rate, 8.1/1000 PYFU; 95% CI, 7.7–8.6). After adjustment, there was no difference between the 5 HCV strata in incidence of DM (global P = .33). Hypertension (22.2%; 95% CI, 17.5%–26.2%) and body mass index >25 (22.0%; 95% CI, 10.4%–29.7%) had the largest population-attributable fractions for DM.
Conclusions
HCV coinfection and HCV cure were not associated with DM in this large study. The biggest modifiable risk factors were hypertension and obesity, and continued efforts to manage such comorbidities should be prioritized.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK
2 CHIP, Rigshospitalet, Copenhagen, Denmark
3 University Hospital Bonn, Bonn, Germany
4 Helsinki University Hospital, Helsinki, Finland
5 Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland
6 Nordsjællands Hospital, Hillerød, Denmark
7 Mortimer Market Centre, London, UK
8 Hôtel-Dieu, AP-HP, Paris, France
9 Sorbonne Université, IPLESP Inserm UMR-S1136, AP-HP, Paris, France
10 University Hospital of Cologne, Cologne, Germany
11 University of Modena and Reggio Emilia, Modena, Italy
12 Hospital Clinic, Barcelona, Spain
13 University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
14 Hadassah Hospital, Jerusalem, Israel
15 Skane University Hospital, Malmö, Sweden
16 Medical University of Innsbruck, Innsbruck, Austria
17 Gomel Regional Centre for Hygiene, Gomel, Belarus
18 Centre for HIV/AIDS & Infectious Diseases, Kaliningrad, Russia
19 Charles University in Prague and Na Bulovce Hospital, Prague, Czech Republic
20 Poznan University of Medical Sciences, Poznan, Poland
21 Carol Davila University of Medicine and Pharmacy, Bucharest, Romania